A population-based study evaluating the
✍
Daniel Y. C. Heng; Kim N Chi; Nevin Murray; Tao Jin; Jorge A Garcia; Ronald M Bu
📂
Article
📅
2009
🏛
John Wiley and Sons
🌐
English
⚖ 183 KB
👁 1 views
## Abstract ## BACKGROUND: Sunitinib has replaced interferon (IFN) as a first‐line standard of care in the treatment of metastatic renal cell carcinoma (RCC). This study aimed to determine overall survival and to confirm effectiveness in a population that includes poor prognosis patients. ## METH